5-aminolevulinic acid
Phase 1- Indications
- Glioblastoma, High-grade glioma
Company intelligence / Profile preview
The company’s first-in-human Phase 1/2 trial for recurrent or refractory high-grade gliomas demonstrated a strong safety profile. Median overall survival was doubled and progression-free survival improved threefold compared to historical data. The therapy selectively targets cancer cells while sparing healthy tissue. FDA Orphan Drug and Fast Track designations have been granted for their lead program.[3][4][6][7][9]
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Alpheus Medical.